Core Insights - Teleflex reported revenue of $795.41 million for Q4 2024, a year-over-year increase of 2.8%, with an EPS of $3.89 compared to $3.38 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $813.53 million by 2.23%, while the EPS exceeded the consensus estimate of $3.86 by 0.78% [1] Financial Performance - The company’s shares returned -1.6% over the past month, slightly outperforming the Zacks S&P 500 composite's -2.2% change [3] - Teleflex holds a Zacks Rank 4 (Sell), indicating potential underperformance against the broader market in the near term [3] Geographic Revenue Breakdown - Americas revenue reached $540.80 million, exceeding the average estimate of $468.16 million by 20% year-over-year [4] - Asia revenue was $93.60 million, below the average estimate of $99.25 million [4] - EMEA revenue totaled $161 million, slightly below the average estimate of $164.54 million [4] Segment Revenue Analysis - Interventional revenues were $160.40 million, surpassing the average estimate of $158.48 million, reflecting an 18.3% year-over-year increase [4] - Interventional Urology revenues were $84.90 million, falling short of the average estimate of $92.23 million, marking an 8.7% decline year-over-year [4] - OEM revenues were $85.40 million, slightly above the average estimate of $84.13 million, with a year-over-year increase of 3.4% [4] - Vascular Access revenues were $189.30 million, below the average estimate of $201.17 million, but showing a 1.4% increase year-over-year [4] - Anesthesia revenues were $95.30 million, below the average estimate of $104.17 million, reflecting a 3% decline year-over-year [4] - Other revenues were $58.20 million, exceeding the average estimate of $55.18 million, but showing a 14.7% decline year-over-year [4] - Surgical revenues were $121.90 million, above the average estimate of $118.18 million, with an 11.2% year-over-year increase [4]

Core Insights - Teleflex (TFX) reported quarterly earnings of $3.89 per share, exceeding the Zacks Consensus Estimate of $3.86 per share, and showing an increase from $3.38 per share a year ago, resulting in an earnings surprise of 0.78% [1] - The company posted revenues of $795.41 million for the quarter ended December 2024, which was below the Zacks Consensus Estimate by 2.23%, but an increase from $773.91 million year-over-year [2] - Teleflex has surpassed consensus EPS estimates in all four of the last quarters, but has only topped revenue estimates once in the same period [2] Earnings Outlook - The sustainability of Teleflex's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.52 on revenues of $769.15 million, and for the current fiscal year, it is $15.18 on revenues of $3.22 billion [7] Industry Context - The Medical - Instruments industry, to which Teleflex belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Teleflex's stock may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]